Cathelicidin (LL‐37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4–NF‐κB–NLRP3 signaling
Immunity, Inflammation and Disease · 2023
DOI: 10.1002/iid3.1032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Feifei Si und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Cardiovascular Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Techno…. Hauptthemen laut MEDLINE: Cathelicidins, Mucocutaneous Lymph Node Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Kawasaki disease (KD) is a type of vasculitis with an unidentified etiology. Cathelicidin (LL‐37) may be involved in the development of the KD process; therefore, further research to investigate the molecular mechanism of LL‐37 involvement in KD is warranted.
Methods
Enzyme‐linked immunosorbent assay (ELISA) was used to detect the levels of tumor necrosis factor‐α (TNF‐α), interleukin (IL)‐1β, NLRP3, and LL‐37 in the sera of healthy subjects, children with KD, and children with pneumonia. Subsequently, human recombinant LL‐37 or/and toll‐like receptors 4 (TLR4)‐specific inhibitor TAK‐242 stimulated human coronary artery endothelial cells (HCAECs), CCK‐8 was used to detect cell proliferation, flow cytometry to detect apoptosis, transmission electron microscopy to observe cytoskeletal changes, Transwell to measure cell migration ability, ELISA to detect inflammatory factor levels, Western blot analysis to analyze protein levels of toll‐like receptors 4 (TLR4) and NF‐κB p‐65, and quantitative real‐time polymerase chain reaction (qRT‐PCR) to determine LL‐37, NLRP3 mRNA levels.
Results
In this study, we found that the level of LL‐37 was highly expressed in the serum of children with KD, and after LL‐37 stimulation, apoptosis was significantly increased in HCAECs, and the expression levels of TLR4, NLRP3 and inflammatory factors in cells were significantly enhanced. Intervention with the TLR4‐specific inhibitor TAK‐242 significantly alleviated the LL‐37 effects on cellular inflammation, TLR4, NLRP3 promotion effect.
Conclusions
Our data suggest that LL‐37 induces an inflammatory response in KD coronary endothelial cells via TLR4‐NF‐κB‐NLRP3, providing a potential target for the treatment of KD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Cardiovascular Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Feifei Si
Zitieren
APA
Si, F., Lu, Y., Wen, Y., Chen, T., Zhang, Y., & Yang, Y. (2023). Cathelicidin (LL‐37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4–NF‐κB–NLRP3 signaling. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1032
Vancouver
Si F, Lu Y, Wen Y, Chen T, Zhang Y, Yang Y. Cathelicidin (LL‐37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4–NF‐κB–NLRP3 signaling. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.1032
BibTeX
@article{Si2023,
author = {Si, Feifei and Lu, Yaheng and Wen, Yizhou and Chen, Tingting and Zhang, Yingzi and Yang, Yanfeng},
title = {Cathelicidin (LL‐37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4–NF‐κB–NLRP3 signaling},
journal = {Immunity, Inflammation and Disease},
year = {2023},
doi = {10.1002/iid3.1032}
}
EUVIMED